Bio Rad Labs Cl B (BIO.B) 145.73 $BIO.B Bio-Rad Unveils

New Post Public Reply Private Reply Replies (0) Message Board

Jun 14, 2016 at 1:19 AM

Bio Rad Labs Cl B (BIO. 145.73 $BIO.B

Bio-Rad Unveils Amplichek II Quality Control, the First in a Series of Controls for the Molecular Diagnostics Testing Market
Marketwired - Mon May 23, 7:30AM CDT
HERCULES, CA--(Marketwired - May 23, 2016) - Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO., a global provider of life science research and clinical diagnostic products, today announced its entry into the rapidly growing molecular diagnostics testing market with the launch of Amplichek™ II quality control, which was recently issued a de novo clearance from the U.S. Food and Drug Administration (FDA).
BIO: 144.84 (-1.74), BIO.B: 145.73 (-3.31)

Bio-Rad posts 1Q profit
Automated Insights - Thu May 05, 4:12PM CDT
HERCULES, Calif. (AP) _ Bio-Rad Laboratories Inc. (BIO. on Thursday reported first-quarter profit of $12.3 million.
BIO: 144.84 (-1.74), BIO.B: 145.73 (-3.31)

Bio-Rad Reports First-Quarter 2016 Currency-Neutral Revenue Growth of Nearly 4 Percent
Marketwire Canada - Thu May 05, 3:16PM CDT
HERCULES, CA--(Marketwired - May 5, 2016) - Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO., a global provider of life science research and clinical diagnostic products, announced financial results today for the first quarter ended March 31, 2016.
BIO: 144.84 (-1.74), ILMN: 139.71 (-1.91), BIO.B: 145.73 (-3.31)

Bio-Rad Expands Its Cell Biology Portfolio With High Performance Flow Cytometer
Marketwired - Mon Feb 08, 3:30PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO. and Propel Labs today announced that Bio-Rad has acquired a high performance analytical flow cytometer platform from Propel Labs that will enable advanced and novice users to perform basic and multi-parameter cytometry for a wide range of applications and chemistries. Bio-Rad expects to launch the instrument later this year.
BIO: 144.84 (-1.74), BIO.B: 145.73 (-3.31)

Bio-Rad to Report Fourth-Quarter and Full-Year 2015 Financial Results Thursday, February 25, 2016
Marketwired - Tue Feb 02, 2:36PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO., a global provider of life science research and clinical diagnostic products, will report financial results fourth quarter and full year 2015 on Thursday, February 25, 2016, following the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
BIO: 144.84 (-1.74), BIO.B: 145.73 (-3.31)

Bio-Rad Joins Food Safety Consortium With IBM and Mars, Incorporated
Marketwired - Tue Jan 12, 8:30AM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO., a global provider of life science research and clinical diagnostic products, today announced that it has joined the Consortium for Sequencing the Food Supply Chain established in 2015 by scientists from IBM Research (NYSE: IBM) and Mars, Incorporated. The consortium is combining advanced genomics with new informatics tools to observe microbial communities in food and detect hazards in the food supply chain that can threaten safety.
IBM: 151.28 (-1.09), BIO: 144.84 (-1.74), BIO.B: 145.73 (-3.31)

Bio-Rad Named One of the 2015 Top 100 Bay Area Innovators by Thomson Reuters
Marketwired - Tue Jan 05, 3:15PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO., a global provider of life science research and clinical diagnostic products, today announced that it was named one of the "Thomson Reuters 2015 Top 100 Bay Area Innovators."
BIO: 144.84 (-1.74), BIO.B: 145.73 (-3.31)

Bio-Rad's TANGO infinity Receives FDA 510(k) Clearance for U.S. Markets
Marketwired - Mon Dec 21, 3:21PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO., a global provider of life science research and clinical diagnostic products, today announced that it has received U.S. Food and Drug Administration clearance to market its TANGO infinity(R) system in the U.S. The system automates routine blood typing and screening testing procedures for patients and donors.
BIO: 144.84 (-1.74), BIO.B: 145.73 (-3.31)

Bio-Rad Receives FDA Clearance for Its D-100 System for A1c Testing
Marketwired - Wed Dec 16, 5:19PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO., a global provider of life science research and clinical diagnostic products, today announced that its D-100(TM) System for A1c testing has obtained clearance from the U.S. Food and Drug Administration to monitor the long-term blood glucose control of individuals with diabetes, as an aid in the diagnosis of diabetes, and to help identify those who may be at risk for developing the disease.
BIO: 144.84 (-1.74), BIO.B: 145.73 (-3.31)

Bio-Rad Reports Third-Quarter 2015 Financial Results
Marketwired - Tue Nov 03, 3:15PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO., a global provider of life science research and clinical diagnostic products, announced financial results today for the third quarter ended September 30, 2015.
BIO: 144.84 (-1.74), BIO.B: 145.73 (-3.31)

Bio-Rad to Report Third-Quarter 2015 Financial Results Tuesday, November 3, 2015
Marketwired - Mon Oct 19, 3:15PM CDT
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO., a global provider of life science research and clinical diagnostic products, will report financial results for the third quarter 2015 on Tuesday, November 3, 2015, following the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
BIO: 144.84 (-1.74), BIO.B: 145.73 (-3.31)

Bio-Rad Introduces the IH-500, a Fully Automated Random Access System for Blood Typing and Screening
Marketwired - Mon Aug 03, 7:30AM CDT
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO., today announced the launch of the IH-500, a fully automated random access system for blood typing and screening, providing small and medium-size transfusion medicine laboratories fast and reliable results in a 24/7 environment. The IH-500 system is available in Europe, Asia, Africa, Australia, and Latin America.
BIO: 144.84 (-1.74), BIO.B: 145.73 (-3.31)

Bio-Rad Announces U.S. FDA Pre-Market Approval for the BioPlex 2200 HIV Ag-Ab Assay, a Novel Next Generation HIV Diagnostic Test
Marketwired - Tue Jul 28, 3:15PM CDT
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO., a global provider of life science research and clinical diagnostic products, today announced that it has received U.S. Food and Drug Administration pre-market approval to offer its BioPlex(R) 2200 HIV Ag-Ab assay, the company's 5th generation HIV diagnostic test.
BIO: 144.84 (-1.74), BIO.B: 145.73 (-3.31)

Bio-Rad to Report Second-Quarter 2015 Financial Results Thursday, August 6, 2015
Marketwired - Fri Jul 10, 3:29PM CDT
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO., a global provider of life science research and clinical diagnostic products, will report financial results for the second quarter 2015 on Thursday, August 6, 2015, following the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Daylight Time (5 PM Eastern Daylight Time) that day.
BIO: 144.84 (-1.74), BIO.B: 145.73 (-3.31)

Bio-Rad Announces FDA Clearance for Diagnosing Diabetes With Its VARIANT II TURBO HbA1c Kit - 2.0
Marketwired - Tue Jun 09, 3:29PM CDT
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO., a global provider of life science research and clinical diagnostic products, today announced that its VARIANT(TM) II TURBO HbA1c Kit - 2.0 has obtained clearance from the U.S. Food and Drug Administration for use as an aid in diagnosing diabetes and identifying people who may be at risk for developing the disease. This approval enhances the traditional use of the instrument by also providing the ability to screen and diagnose diabetes.
BIO: 144.84 (-1.74), BIO.B: 145.73 (-3.31)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Group 1 Automotive Q3 2026: Profits Soar, Revenues Dip

Profits Up, Revenues Down Here's a tale for the books—Group 1 Automotive reports their third quarter results of 2026 and it's a bit like swapping a thunderstorm for a hurricane. Net income from continuing operations stomped on last year's figures, clocking in at a hefty $102.9 million compared to a skimpy $13.1 million. But don't let that fool you, their total revenues...

MidCap Financial Faces Scrutiny Amid Ares Capital Merger

MidCap Financial's Merger Sparks Legal Action Nobody expects their investments to end up in a courtroom drama, but here we are. MidCap Financial Investment Corporation (NASDAQ: MFIC) is under the microscope, thanks to attorney Juan Monteverde's M&A Class Action Firm. From their perch in the Empire State Building, Monteverde & Associates, celebrated as a top dog in the ISS...

Endava Faces Class Action: Investors Eye Their Next Move

A Mess That Investors Can't Ignore If you're holding onto Endava plc shares, you've probably felt that gut-punch lately. Yeah, things are getting heated with a class action lawsuit alleging the company played fast and loose with its accounting practices. The complaint's about some shady dealings that may have thrown off investors' perceptions. The Core Allegations This...

Tabañero Spices Up Holidays with $10 Gift Sets

Hot Sauce, Spicy Gifting, and Bold Barbecue When holiday cheer mixes with a dash of heat, you end up with something as electrifying as Tabañero's latest offerings. This Florida-based player is nudging its way into the gift-giving scene with a lineup that's as spicy as it is thoughtful. Frankly, if you're scrambling for stocking stuffers or a memorable Secret Santa...

Heritage Wines Meet Non-Alcoholic Trend: New Deal

Wine Industry Shifts Gears Well, here's a twist that might just shake up the wine racks. C. Mondavi & Family, from the historic Charles Krug estate, is aligning with Missing Thorn—a name gaining traction in the non-alcoholic wine scene. It’s a move that not only raises eyebrows but could also expand your wine-tasting options come your next sober night out. So what...

Webull Faces Class Action: Deadline Looms Dec 2026

Sinking Shares: The Webull Saga Unfolds Shady business practices can really make a stock take a nosedive, and that's what's happening with Webull Corporation, trading under NASDAQ:BULL. The alarm bells started ringing when the truth about their operations and ties to China came out. Turns out, what looked like a stable American fintech platform had its roots digging deep...

Valmet's Strategic Moves and Financial Gains Explained

Valmet's Strategic Playbook for Growth Anyone keeping tabs on Valmet's recent parade of press releases knows they're on a darn aggressive growth spurt. Talk about shaking things up with a firm grip on the paper and forest products sector and beyond. Their interim review from January to September 2026 spells it out with strong orders received and a solid increase in...

Veterinary Implants Market to Hit $0.98B by 2031

Veterinary Implants Market: A Growth Tale Something's stirring in the veterinary world, my friend. The Veterinary Implants Devices Market is hitting some serious strides, and we're looking at a valuation touching nearly $0.98 billion by 2031. If you're eyeing the veterinary sector, it's time to sharpen those pencils and take notes on where the trend winds are blowing....

Brinker International Posts Solid Q1 2027 Earnings

Strong Earnings Highlight a Winning Streak Brinker International, folks, has done it again. With the latest release of their first quarter fiscal 2027 results, it’s clear they’ve been hitting the right notes, especially at Chili’s. The numbers don't lie—trust me, I've seen my fair share of earnings calls, and this one's got meat on the bones. Let’s break it...

Tribal Tech Triumph: ILINX Boosts Proposal Efficiency

A New Era for Tribal Operations Well, here's a headline that might've slipped under your radar, but it’s got some serious implications. Over in Olympia, Washington, ImageSource, Inc., the brains behind the ILINX platform, just scored a home run with an automated system for crafting Tribal Indirect Cost Rate Proposals (ICRPs). This ain't just gadget talk; this is a...